Quality of Life for Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco

About this trial

Central nervous system (CNS) metastases including breast cancer brain metastases (BCBMs) and leptomeningeal disease (LMD) are common affecting up to 30% of patients with metastatic breast cancer (MBC). The goal of this research is to understand symptom burden and quality of life trajectories in this population and how treatments guide care management decisions.

Eligibility criteria

Qualifiers

Be male or female 18 years of age or older.

Have stage 4 (metastatic) breast cancer with spread to the brain parenchyma and/or leptomeninges.

Have the intention to start or continue anticancer therapy.

Be able to provide informed consent.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Health-Related Quality of Life (QOL) questionnaires
  • Medical Chart Review

Treatment groups

200 Participants
are divided into 1 treatment group